Literature DB >> 10401522

Endogenous salivary inhibitors of human immunodeficiency virus.

D C Shugars1, A L Alexander, K Fu, S A Freel.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) is rarely transmitted through salivary secretions, due in part to the presence of endogenous inhibitors. Here, the protective characteristics of the intraoral environment are summarized and inhibitory factors that reduce HIV-1 infectivity in vitro described, focusing on secretory leucocyte protease inhibitor (SLPI), a 12-kDa mucosal protein that blocks HIV infection in several cell-culture systems. SLPI appears to interact with a cellular surface molecule to limit viral entry into target cells. To determine whether the inhibitor has a similar role in vivo, the contribution of salivary SLPI to anti-HIV-1 activity was assessed. Whole unstimulated filtered salivas from infected and uninfected donors contained similar concentrations of the inhibitor. Depletion from SLPI filtered saliva produced a corresponding loss of inhibitory activity. In general, filtered whole salivas obtained from 10 donors had antiviral activities that correlated positively with SLPI concentrations. However, some samples having SLPI well below the concentration required for inhibitory activity in vitro exhibited modest inhibition, suggesting the presence of other anti-HIV-1 components in oral fluids. Thus, SLPI is a major but not sole inhibitor of this virus in saliva.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401522     DOI: 10.1016/s0003-9969(99)00003-5

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  18 in total

Review 1.  The significance of oral health in HIV disease.

Authors:  I L Chapple; J Hamburger
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain.

Authors:  Hua Xie; Natalya I Belogortseva; Jie Wu; Wei-Hong Lai; Chin-ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

5.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

6.  HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors.

Authors:  Patricia B Pavlinac; Stephen E Hawes; Geoffrey S Gottlieb; Awa Gaye; Charlotte F N'Diaye; Cathy W Critchlow; Papa Salif Sow; Qinghua Feng; Nancy B Kiviat
Journal:  Sex Transm Infect       Date:  2012-02       Impact factor: 3.519

7.  Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.

Authors:  Catherine Rougeot; Michaël Messaoudi; Véronique Hermitte; Anne Gaëlle Rigault; Thierry Blisnick; Christophe Dugave; Didier Desor; François Rougeon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-30       Impact factor: 11.205

Review 8.  Acute HIV revisited: new opportunities for treatment and prevention.

Authors:  Christopher D Pilcher; Joseph J Eron; Shannon Galvin; Cynthia Gay; Myron S Cohen
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 9.  Oral infectious diseases: a potential risk factor for HIV virus recrudescence?

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Oral Dis       Date:  2009-04-02       Impact factor: 3.511

10.  Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.

Authors:  Amit Chattopadhyay; Laurie R Gray; Lauren L Patton; Daniel J Caplan; Gary D Slade; Hsaio-Chuan Tien; Diane C Shugars
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.